# Ovarian Neoplasms trials: 387 new since Nov 2024

Updated November 9, 2026.

387 clinical studies in Ovarian Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 149 have an industry sponsor and 327 are recruiting or about to. The newest, NCT07926048, was posted on November 9, 2026: A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Qilu Pharmaceutical Co., Ltd.).

## The full list

New Ovarian Neoplasms clinical trials: 387 rows for $19.35, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 17 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 387
- Industry sponsored: 149
- Recruiting or not yet: 327
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 387, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| November 6, 2026 | NCT07923214 | A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors | Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer, Other Solid Tumors | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923214) |
| November 4, 2026 | NCT07915336 | Peer Ambassador in Gyn Onc Trials | Abramson Cancer Center at Penn Medicine | Not applicable | Enrolling by invitation | Ovarian Cancer | 125 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915336) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| October 29, 2026 | NCT07905677 | Phase 1 Study of VT-101 in Advanced Ovarian Cancer | Michael J. Goodheart | Phase 1 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 22 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905677) |
| October 28, 2026 | NCT07902375 | Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers | Universiteit Antwerpen | Not applicable | Recruiting | Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, Postmenopausal Bleeding... | 730 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902375) |
| October 27, 2026 | NCT07896421 | Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and... | AbbVie | Observational | Recruiting | Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer... | 500 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896421) |
| October 26, 2026 | NCT07895212 | Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic Lymphadenectomy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not applicable | Recruiting | Ovary Cancer, Cervical Cancer, Endometrial Cancer | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895212) |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| October 22, 2026 | NCT07889843 | Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer | Hellenic Cooperative Oncology Group | Observational | Recruiting | High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive | 200 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889843) |
| October 20, 2026 | NCT07883798 | Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions | Affidea Nu-med Center of Oncological DIagnostics and Therapy | Observational | Recruiting | Cervical Cancer, Gynecologic Cancer, Endometrial Cancer, Uterine Cancer, Uterine Sarcoma, Ovarian Cancer, Fallopian... | 500 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883798) |
| October 20, 2026 | NCT07883551 | AI Analysis of CT Scans to Classify Ovarian Tumours as Benign, Borderline or Malignant Before Surgery | Catharina Ziekenhuis Eindhoven | Observational | Not yet recruiting | Ovarian Cancer, Ovarian Tumor, Borderline Ovarian Tumor | 1,300 | Belgium, Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883551) |
| October 20, 2026 | NCT07882485 | Effects of Web-Based Ovarian Cancer Awareness Education on Women's Health Beliefs and Risk-Reducing Behaviors | Ege University | Not applicable | Not yet recruiting | Ovarian Cancer | 82 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882485) |
| October 15, 2026 | NCT07876349 | EHR Intervention to Increase HBOC Genetic Testing | Columbia University | Not applicable | Recruiting | Breast Cancer, Ovarian Cancer, Hereditary Cancer Syndrome | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876349) |
| October 13, 2026 | NCT07872644 | Safety in Ovarian Cancer for Average-Risk Women - Analysis | Mercy BioAnalytics, Inc. | Not applicable | Not yet recruiting | Ovarian Cancer | 1,750 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872644) |
| October 13, 2026 | NCT07870278 | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) | Merck Sharp & Dohme LLC | Phase 1 | Not yet recruiting | Ovarian Neoplasms, Endometrial Neoplasms | 80 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870278) |
| October 9, 2026 | NCT07869186 | Dermatological Effects and Quality of Life in Oncology Patients | European Institute of Oncology | Not applicable | Not yet recruiting | Breast Cancer, Ovarian Cancer, NSCLC (Non-small Cell Lung Cancer), Melanoma (Skin Cancer), Gynecological Cancer | 300 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869186) |
| October 6, 2026 | NCT07860203 | Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery | Catherin Zhang | Not applicable | Recruiting | Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus, Endometriosis, Endometrial Cancer, Cervical Cancer, Ovarian Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860203) |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| September 30, 2026 | NCT07849543 | Contrast-enhanced Ultrasound Evaluation of Indeterminate Ovarian Lesions: Prospective Multicenter Study | Thomas Jefferson University | Not applicable | Not yet recruiting | Ovarian Cancer, Adnexal Lesion | 190 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849543) |
| September 28, 2026 | NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 53 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843303) |
| September 21, 2026 | NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Dana-Farber Cancer Institute | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832227) |
| September 16, 2026 | NCT07822646 | A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer | Chinese PLA General Hospital | Phase 3 | Recruiting | Ovarian Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822646) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | Australia, Brazil, Canada, China, Germany, India, Italy, Japan, South Korea... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 11, 2026 | NCT07815951 | Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid Tumors | Yong He | Phase 1 | Not yet recruiting | Solid Tumors, Carcinoma, Ovarian Neoplasms, Endometrial Neoplasms Malignant, Testicular Neoplasms, Lung Neoplasms... | 8 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815951) |
| September 11, 2026 | NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | University of Colorado, Denver | Phase 2 | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer, High Grade Serous Adenocarcinoma of Ovary | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815704) |
| September 11, 2026 | NCT07814872 | A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | Harvard Medical School (HMS and HSDM) | Observational | Not yet recruiting | Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic... | 30,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814872) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| September 9, 2026 | NCT07809659 | CanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA) | Instituto Portugues Oncologia de Lisboa Francisco Gentil | Not applicable | Recruiting | Ovarian Cancer | 2,130 | Czechia, Greece, Lithuania, Portugal | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809659) |
| September 8, 2026 | NCT07808320 | HERCULES: Ultrasound-Based Liver Involvement Classification in Ovarian Cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Ovarian Cancer, Recurrent Ovarian Cancer | 20 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808320) |
| September 8, 2026 | NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With... | AbbVie | Phase 1 | Recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer... | 130 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807956) |
| September 8, 2026 | NCT07807683 | Circulating Endothelial Cells (CECs) as Potential Predictive/Prognostic Biomarkers in Ovarian Cancer | Centro di Riferimento Oncologico - Aviano | Observational | Completed | Ovarian Cancer | 148 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807683) |
| September 1, 2026 | NCT07797283 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing... | Incyte Corporation | Phase 3 | Not yet recruiting | Ovarian Cancer | 590 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797283) |
| August 28, 2026 | NCT07793201 | Machine Learning Algorithms Incorporating Radiomic Ultrasound Features | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Adnexal Masses | 12,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793201) |
| August 28, 2026 | NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent... | Daiichi Sankyo | Phase 3 | Not yet recruiting | Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian | 600 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791732) |
| August 27, 2026 | NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | Peking University Cancer Hospital & Institute | Early phase 1 | Not yet recruiting | Epithelial Ovarian Cancer, Ovarian Cancer | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790939) |
| August 24, 2026 | NCT07783022 | Real-World Study of Niraparib in First-Line Maintenance Therapy for Advanced Epithelial Ovarian Cancer | Fudan University | Observational | Recruiting | Ovarian Cancer | 1,920 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783022) |
| August 24, 2026 | NCT07782164 | Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study) | Amsterdam UMC, location VUmc | Observational | Recruiting | Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer... | 27 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782164) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 21, 2026 | NCT07779538 | Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Ovarian Cancer | 420 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779538) |
| August 21, 2026 | NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | Phrontline Biopharma | Phase 1/2 | Recruiting | Ovarian Cancer | 150 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778498) |
| August 20, 2026 | NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer | 802 | Israel, South Korea, Taiwan, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776691) |
| August 20, 2026 | NCT07776171 | Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | 176 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776171) |
| August 18, 2026 | NCT07771400 | Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients | Latin American Cooperative Oncology Group | Observational | Not yet recruiting | Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage III... | 320 | Argentina, Brazil, Colombia, Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771400) |
| August 14, 2026 | NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants | Weill Medical College of Cornell University | Not applicable | Not yet recruiting | Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Serous Tubal Intraepithelial Carcinoma, Early Detection... | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764744) |
| August 12, 2026 | NCT07761416 | Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention | St. Joseph's Healthcare Hamilton | Early phase 1 | Not yet recruiting | Ovarian Cancer, Bariatric Surgery, Opportunistic Salpingectomy | 66 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761416) |
| August 12, 2026 | NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors | Peking University Third Hospital | Not applicable | Recruiting | Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer... | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760012) |
| August 11, 2026 | NCT07757711 | Implementation of New Models of Ovarian Carcinoma Resistant to Therapy | Mario Negri Institute for Pharmacological Research | Observational | Not yet recruiting | Ovarian Cancer | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757711) |
| August 10, 2026 | NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic... | ArriVent BioPharma, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer, Metastatic... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755436) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 5, 2026 | NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | Verastem, Inc. | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | 2 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07747506) |
| August 3, 2026 | NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 646 | Israel, Taiwan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743164) |
| August 3, 2026 | NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | City of Hope Medical Center | Not applicable | Recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 126 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741968) |
| July 30, 2026 | NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Gilead Sciences | Phase 1/2 | Recruiting | Ovarian Cancer | 72 | Belgium, Ukraine, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736937) |
| July 29, 2026 | NCT07733505 | Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian... | Odense University Hospital | Phase 1 | Recruiting | Ovarian Cancer | 10 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733505) |
| July 29, 2026 | NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | University of Oklahoma | Observational | Not yet recruiting | Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon... | 2,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732686) |
| July 23, 2026 | NCT07724106 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With... | West China Hospital | Phase 1 | Recruiting | Ovarian Cancer, mRNA Vaccine | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724106) |
| July 22, 2026 | NCT07720180 | Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide... | Medical University of South Carolina | Phase 2 | Not yet recruiting | Ovarian Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07720180) |
| July 22, 2026 | NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | Tufts Medical Center | Phase 2 | Recruiting | Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718854) |
| July 21, 2026 | NCT07716800 | Predictors of Cognitive Decline and Delirium in Older Women With Ovarian Cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Ovarian Cancer, Cognitive Decline, Delirium | 205 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716800) |
| July 20, 2026 | NCT07715747 | A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1 | Recruiting | Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma | 128 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715747) |
| July 20, 2026 | NCT07714668 | A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Recruiting | Ovarian Cancer, Recurrent Ovarian Cancer | 171 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714668) |
| July 14, 2026 | NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Gynecologic Cancer, Cervical Cancer, Endometrial Cancer, Ovary Cancer, Vulvar Cancer | 160 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702721) |
| July 10, 2026 | NCT07694427 | Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) \[BEHOLD-Ovarian03\] | GlaxoSmithKline | Phase 3 | Recruiting | Ovarian Neoplasms | 720 | Argentina, Australia, Canada, Japan, South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694427) |
| July 9, 2026 | NCT07693894 | Innovative Ovarian Cancer Biomarker Assays | National and Kapodistrian University of Athens | Observational | Recruiting | Ovarian Cancer | 2,080 | Czechia, Greece, Lithuania, Portugal, United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693894) |
| July 8, 2026 | NCT07690332 | A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα） | NING LI-GYN | Observational | Not yet recruiting | Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690332) |
| July 8, 2026 | NCT07690189 | Study of NTB-928 in R/R OC | TeneoSeven, Inc. | Phase 1 | Recruiting | Relapsed/Refractory Ovarian Carcinoma | 90 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690189) |
| July 6, 2026 | NCT07684846 | Longitudinal Serum Proteomic Remodeling in Ovarian Cancer | University Medical Centre Ljubljana | Observational | Completed | Ovarian Cancer, Ovarian Cancer Recurrent | 33 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684846) |
| July 6, 2026 | NCT07684612 | A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With... | GlaxoSmithKline | Phase 3 | Recruiting | Ovarian Neoplasms | 690 | Australia, Canada, Japan, South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684612) |
| June 30, 2026 | NCT07676890 | A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With... | West China Hospital | Phase 1 | Recruiting | Ovarian Cancer, mRNA Vaccine | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676890) |
| June 30, 2026 | NCT07676370 | PROV-MESH: Prophylactic Ovarian Cancer MESH | Hospital Vall d'Hebron | Not applicable | Recruiting | Ovarian Cancer | 152 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676370) |
| June 29, 2026 | NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | Shanghai Gynecologic Oncology Group | Phase 1 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancers, Primary, Primary Peritoneal Carcinoma | 19 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674615) |
| June 29, 2026 | NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients | Royal Marsden NHS Foundation Trust | Not applicable | Recruiting | Non Small Cell Lung Cancer, Gastrointestinal Stromal Tumor (GIST), Colorectal Cancer, Biliary Tract Cancer, Ovarian... | 100 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673861) |
| June 29, 2026 | NCT07673835 | Iparomlimab and Tuvonralimab Plus Chemotherapy as Neoadjuvant Therapy for Ovarian Cancer（Phase II） | Obstetrics & Gynecology Hospital of Fudan University | Phase 2 | Not yet recruiting | Ovarian Cancer | 49 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673835) |
| June 26, 2026 | NCT07671937 | INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study | University of Alabama at Birmingham | Not applicable | Recruiting | Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms | 2,748 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671937) |
| June 26, 2026 | NCT07670962 | Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy | Asan Medical Center | Observational | Not yet recruiting | Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670962) |
| June 26, 2026 | NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | XYone Therapeutics, Inc | Phase 1/2 | Recruiting | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ... | 190 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670312) |
| June 25, 2026 | NCT07667751 | An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive... | Bai-Rong Xia | Phase 2 | Recruiting | Ovary Cancer | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667751) |
| June 24, 2026 | NCT07667192 | Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer | Affidea Nu-med Center of Oncological DIagnostics and Therapy | Observational | Recruiting | Recurrent Gynecologic Cancer, Recurrent Uterine Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent... | 500 | Poland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667192) |
| June 24, 2026 | NCT07665515 | Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Epitopea Ltd | Phase 1 | Recruiting | Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 50 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665515) |
| June 24, 2026 | NCT07664735 | A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | Outpace Bio, Inc. | Phase 1 | Recruiting | Endometrial Cancer Recurrent, Endometrial Cancer, Advanced Endometrial Cancer, Ovarian Cancer, Ovarian Cancer... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664735) |
| June 23, 2026 | NCT07663513 | Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer | Fudan University | Phase 2 | Not yet recruiting | Ovarian Cancers | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663513) |
| June 22, 2026 | NCT07660718 | The Use of Artificial Intelligence for Ultrasound Screening of Ovarian Cancer in Postmenopausal Women | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Observational | Active not recruiting | Ovarian Cancer | 100 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660718) |
| June 18, 2026 | NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | Base Therapeutics (Shanghai) Co., Ltd. | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657416) |
| June 16, 2026 | NCT07652073 | A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer | Danatlas Pharmaceuticals Co., Ltd | Phase 2 | Not yet recruiting | Advanced or Metastatic Ovarian Cancer | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652073) |
| June 16, 2026 | NCT07651124 | To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer | Yong Wha Moon | Not applicable | Recruiting | Recurrent Ovarian Cancer | 6 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651124) |
| June 16, 2026 | NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Completed | Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma, Head and Neck Cancers, Glioblastoma, Colorectal Cancer... | 1 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07651020) |
| June 15, 2026 | NCT07648745 | Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer | Prof Gordon Jayson | Phase 2 | Completed | Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 30 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648745) |
| June 15, 2026 | NCT07647653 | Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer | Shandong University | Phase 2 | Not yet recruiting | Ovarian Cancer | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647653) |
| June 12, 2026 | NCT07645716 | Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic Oncology | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Observational | Not yet recruiting | Ovarian Neoplasms, Uterine Neoplasms | 400 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645716) |
| June 11, 2026 | NCT07642791 | Safety of Opportunistic Salpingectomy During Elective Laparoscopic Cholecystectomy. | University of Zurich | Not applicable | Active not recruiting | Ovarian Cancer, Cholecystolithiasis | 300 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642791) |
| June 10, 2026 | NCT07639801 | 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors | Peking University Cancer Hospital & Institute | Not applicable | Not yet recruiting | Prostate Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Solid Tumors, Endometrial Cancer, FAPI, PSMA | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639801) |
| June 10, 2026 | NCT07638410 | Prehabilitation in High-risk Oncologic Surgery | Fox Chase Cancer Center | Not applicable | Recruiting | Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638410) |
| June 10, 2026 | NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | ARCAGY/ GINECO GROUP | Phase 1/2 | Not yet recruiting | Ovarian Cancer | 43 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637851) |
| June 9, 2026 | NCT07636200 | The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer | University of Colorado, Boulder | Not applicable | Recruiting | Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only), Glioblastoma, Stage III Ovarian Cancer, Small Cell... | 250 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636200) |
| June 8, 2026 | NCT07634094 | Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian... | Kalinski, Pawel, MD, PhD | Phase 2 | Not yet recruiting | Ovarian Cancer | 28 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634094) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Haihua Yuan | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| June 4, 2026 | NCT07625137 | Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy | University of British Columbia | Not applicable | Not yet recruiting | Salpingectomy, Laparoscopic Cholecystectomy | 240 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625137) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 17 | September 8, 2026 |
| AbbVie | 6 | October 27, 2026 |
| AstraZeneca | 6 | September 14, 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 5 | October 26, 2026 |
| Merck Sharp & Dohme LLC | 5 | October 13, 2026 |
| Tongji Hospital | 5 | May 18, 2026 |
| Genmab | 4 | October 5, 2026 |
| Fudan University | 4 | August 24, 2026 |
| GlaxoSmithKline | 4 | July 10, 2026 |
| Beijing Biotech | 4 | June 1, 2026 |
| Abramson Cancer Center at Penn Medicine | 3 | November 4, 2026 |
| Peking University Cancer Hospital & Institute | 3 | September 28, 2026 |
| Incyte Corporation | 3 | September 1, 2026 |
| Daiichi Sankyo | 3 | August 28, 2026 |
| Peking University Third Hospital | 3 | August 12, 2026 |
| Shanghai Gynecologic Oncology Group | 3 | June 29, 2026 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 | June 22, 2026 |
| Essen Biotech | 3 | February 13, 2026 |
| Yonsei University | 3 | January 14, 2026 |
| Mayo Clinic | 3 | December 16, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 91 | October 27, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 78 | November 4, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 62 | November 6, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 60 | September 28, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 46 | November 2, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 32 | November 9, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 8 | August 27, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 6 | April 24, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 4 | March 13, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 128 | November 4, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 92 | November 6, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 38 | October 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 28 | September 14, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 26 | August 5, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 25 | September 14, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 24 | September 14, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 21 | August 20, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 20 | September 14, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 19 | September 14, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 18 | October 28, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 15 | September 14, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 13 | September 14, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 12 | October 20, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 10 | September 14, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 10 | September 9, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 9 | August 20, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 9 | July 29, 2026 |
| [Portugal](https://specstream.ai/data/clinical-trials/country/portugal) | 8 | September 9, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 7 | October 22, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 7 | October 20, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 7 | August 18, 2026 |
| [Ireland](https://specstream.ai/data/clinical-trials/country/ireland) | 7 | April 22, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 6 | October 27, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 6 | June 11, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).